4 measures of EHR, clinical documentation effectiveness

Electronic health records (EHRs) have become an integral part of the healthcare system, but how do clinicians view this technology?  In a study conducted by Nuance, researchers analyze multiple factors in how clinicians view and use EHRs in everyday care.

The study used an online survey to ask a variety of questions to C-Suite, IT leadership and additional clinicians to gauge their views on EHRs in healthcare. The study included the following:

When asked how confident they were in their organizations to realize the benefits on EHR:

  • Overall, 83 percent reported confidence in EHRs.
  • 46.7 percent were somewhat confident.
  • 35.9 percent reported being very confident.

When asked how their administrative staff or resources have changed in response to EHRs:

  • 77 percent reported changes in training and support.
  • 63 percent reported changes in software development.
  • 61 percent reported changes in staff involved with information governance.

When asked what the organizations is doing to improve clinicians' satisfaction with EHRs:

  • 82 percent reported improvements in education of staff.
  • 75 percent reported improvements in existing technologies.
  • 67 percent reported improvements in adopting new technologies.

When asked how to further improve the financial impact of EHRs:

  • 67 percent reported the ability to capture reimbursements.
  • 54 percent reported reductions in denied claims.
  • 52 percent reported improved performance under Bundled payments.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.